S. 4472
IntroducedAccelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Updated 2026-08-15
Legislative Impact
Limited Policy Signal
31
Momentum Score
Low Momentum
8
Reauthorizes through FY2031 and revises federal ALS and rare neurodegenerative disease therapy research programs, including grant conditions, FDA planning, and impact reporting
- Require FDA five year plans
- Require grant impact reports
